Connection
Stuart Lind to Breast Neoplasms
This is a "connection" page, showing publications Stuart Lind has written about Breast Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.168 |
|
|
|
-
Zhou J, Zhang S, Xue J, Avery J, Wu J, Lind SE, Ding WQ. Activation of peroxisome proliferator-activated receptor a (PPARa) suppresses hypoxia-inducible factor-1a (HIF-1a) signaling in cancer cells. J Biol Chem. 2012 Oct 12; 287(42):35161-35169.
Score: 0.037
-
Zhang X, Yu H, Lou JR, Zheng J, Zhu H, Popescu NI, Lupu F, Lind SE, Ding WQ. MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. J Biol Chem. 2011 Jan 14; 286(2):1429-35.
Score: 0.033
-
Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009 Jul 01; 8(13):2031-40.
Score: 0.030
-
Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009 Mar 15; 8(6):909-15.
Score: 0.029
-
Lee J, Li S, Torbenson M, Liu QZ, Lind S, Mulvihill JJ, Bane B, Wang J. Leiomyosarcoma of the breast: a pathologic and comparative genomic hybridization study of two cases. Cancer Genet Cytogenet. 2004 Feb; 149(1):53-7.
Score: 0.021
-
Deng XS, Wang S, Deng A, Liu B, Edgerton SM, Lind SE, Wahdan-Alaswad R, Thor AD. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle. 2012 Jan 15; 11(2):367-76.
Score: 0.009
-
Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle. 2011 Sep 01; 10(17):2959-66.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|